Tags : Hypera Pharma

PharmaShots Weekly Snapshot (March 02-06, 2020)

1. Mount Sinai Signs a Multi-Year Collaboration with Harbour BioMed to Develop Novel Biotherapies for Multiple Cancer Indications and COVID-19 Published: Mar 06, 2020 | Tags: Mount Sinai, Signs, Multi-Year, Collaboration, Harbour BioMed, Develop, Novel Biotherapies, Multiple Cancer Indications, COVID-19 2. AstraZeneca Reports Results of Imfinzi and Tremelimumab in P-III DANUBE Study for Unresectable Stage IV […]Read More

Takeda to Divest a Portfolio of Select OTC and Non-Core

Shots: Takeda will divest a portfolio of ~18 select OTC and prescription pharmaceutical assets including Neosaldina, Nesina, and Dramin sold in Brazil, Mexico, Argentina, Colombia, Ecuador, Panama and Peru to Hypera for a total value ~$825M. The transaction is expected to be close in H2’20 Takeda expects that its ~300 employees supporting the divested assets […]Read More